Roche develops PCR test for Bundibugyo Ebola virus within six days to support outbreak detection
Rapid-response assay supports early detection and surveillance during ongoing Ebola outbreak
11 Jun 2026Product news
Roche, through its subsidiary TIB MOLBIOL, has developed a Research Use Only (RUO) molecular PCR test for the rapid detection of the rare Ebola Bundibugyo virus. Created within six days of the Bundibugyo genome sequence being published, the assay is designed for use on the LightCycler® 480 Real-Time PCR System, the LightCycler® 480 Instrument II, the LightCycler® PRO System and the cobas® z 480 analyzer.
The test supports outbreak response efforts in Central and East Africa, including the Democratic Republic of Congo (DRC) and Uganda, and addresses the urgent need for early, accurate detection and surveillance of this emerging Ebola variant.
With no approved vaccines or specific treatments currently available for Bundibugyo virus disease, delays in detection can contribute to increased transmission and larger outbreaks. Rapid, accurate molecular testing is therefore a key component of effective outbreak control strategies.
The new RUO PCR assay targets the Bundibugyo virus, a rare species of Ebola. By enabling laboratories to swiftly establish testing capabilities, the assay is intended to help contain outbreaks and provide critical surveillance data to monitor any further spread.
TIB MOLBIOL’s rapid response library and assay design
TIB MOLBIOL operates at the frontline of outbreak response. The company maintains a rapid response library of 15,000 test pre-designs across a wide range of pathogens and more than 3,000 positive control materials. This extensive library, combined with expertise in oligonucleotide synthesis, enabled TIB MOLBIOL to evaluate multiple primer and probe combinations for the rare Ebola Bundibugyo virus within hours rather than weeks.
This off-the-shelf approach is supported by the immediate mobilization of TIB MOLBIOL’s workforce and facility resources as soon as outbreaks are identified. This model allows laboratories to access ready-to-use assay designs quickly, supporting faster deployment of testing during critical early phases of an outbreak.
Ahead of fully approved diagnostic availability, RUO tests are shipped directly to laboratories where they can be validated. This early access is essential for initial outbreak response, surveillance and research. Validation of a product as an in vitro diagnostic (IVD) or for emergency use can take months or even years, so RUO assays help bridge the gap between the emergence of a pathogen and the availability of fully approved diagnostic solutions.
Real-world performance evaluation using clinical samples
Using real clinical samples, the performance and specificity of the Bundibugyo assay were rapidly evaluated by TIB MOLBIOL’s network of independent reference laboratories. These evaluations provided critical real-time feedback on the assay’s ability to detect the Bundibugyo variant, supporting laboratories and public health authorities in making informed decisions about its use in outbreak settings.
Strengthening Ebola testing capacity in Africa
Roche is working directly with public health laboratories and authorities in affected regions to bring PCR testing for the Bundibugyo virus closer to the Ebola outbreak frontlines. This approach supports faster detection in line with WHO guidance to strengthen laboratory capacity and ensure rapid access to testing.
As a long-standing partner in healthcare infrastructure across the African continent, Roche leverages local partnerships and regional supply chains to make critical surveillance tools accessible to reference laboratories and public health institutions. These capabilities are particularly important during emergencies, when timely access to reliable testing can influence the trajectory of an outbreak.
Track record in rapid-response molecular diagnostics
The Bundibugyo virus test is the latest in a series of rapid-response molecular solutions for infectious diseases produced at scale by Roche. Previous responses include assays for Mpox in 2022, Covid-19 in 2020, ZIKA in 2015, Ebola (Zaire species) in 2014/15, MERS in 2012, H1N1 swine flu in 2009, H5N1 bird flu in 2005 and SARS in 2003.
Most recently, the team at TIB MOLBIOL developed and deployed an Andes virus test following a cruise ship outbreak of Hantavirus Disease. This history of rapid assay development demonstrates Roche’s and TIB MOLBIOL’s ongoing commitment to supporting global outbreak preparedness and response.
“In outbreak situations, we recognize the ability to respond quickly is critical, and diagnostics are among the first vital tools needed,” said Dr. Marcus Droege, CEO of TIB MOLBIOL. “Research-use assays play a crucial role in the first phase of the outbreak response, and our focus is on working closely with laboratories to establish testing capability quickly, support surveillance and response efforts, and enable faster, more informed decision-making when it matters most.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related products
Request Quote for All Products
LightCycler® Pro System
RocheA qPCR system designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories. Leveraging the robustness and proven technology of the LightCycler® 4801, the LightCycler® PRO integrates innovative technology and Roche manufacturing to deliver accurate real-time PCR results, flexible solutions to your workflow, and an improved user experience to your lab.
LightCycler® 480 Instrument II
Rapid high-throughput, plate-based real-time PCR amplification and detection instrument.
LightCycler® 480 Real-Time PCR System
The Roche LightCycler 480 System - Another breakthrough in real-time PCR analysis of gene expression and melting curve-based mutation analysis.The Roche LightCycler 480 RT-PCR System combines amazing speed with exceptional accuracy and will meet the needs of a broad range of scientific applications in genomics research including array validation, gene-knockdown studies, and SNP analysis.This Roche Light Cycler PCR supports all current probe formats and applications and its built-in versatility allows adaptation to future technological advances in genomics research.Customer benefits from the Roche LightCycler® 480 System: Speed – rapid temperature control for superb specificity and yield.The LightCycler 480 PCR System utilizes a novel block technology to allow the rapid heating and cooling required to complete a 40-cycle, 384-well quantitative PCR run in less than 40 minutes and leads to extraordinary well-to-well temperature homogeneity and maximized inter-well, inter-cycle reproducibility. Accuracy – unbiased conditions for unambiguous results Special arrangement of optical components ensures the uniform collection of signals across the plate and makes analysis independent of sample position or differences in reaction volume. Versatility – utmost flexibility for maximum efficiency Five excitation and six emission filters of the Roche LightCycler allow you to work with the assay format of your choice, including SYBR Green I, hydrolysis probes, probes, probes, Molecular Beacons, and others. High-performance optical system from the LightCycler 480Fluorescence excitation by a high-intensity xenon lamp, and a specially developed signal-collection system, result in maximal sensitivity for any assay format in all channels. Additional Features of the LightCycler 480 PCR System: Customizable modular system concept Building on the principles of the well-established, performance-proven LightCycler® Software 4.0, the Roche LightCycler® 480 platform comes equipped with modules for run control, Tm calling, and absolute quantification. Further customize your system to your specific needs by adding separately offered advanced analysis modules. Especially developed reagents A tailor-made hot-start PCR enzyme master mix is available for each type of LightCycler® 480 application. Built on Roche Diagnostics’ performance proven FastStart technology, these reagents ensure optimal reproducibility and high dynamic ranges. Perfect integration into laboratory workflow Compatibility for automated sample-preparation, automated loading and connectivity to laboratory information management systems (LIMS) for integrated workflow monitoring offer uncompromising adaptability for a perfect fit.
Frequently asked questions
How does Roche’s RUO PCR test improve early detection of the Ebola Bundibugyo virus in Central and East Africa?
Roche, through TIB MOLBIOL, developed a Research Use Only PCR assay for rapid detection of the rare Ebola Bundibugyo virus within six days of the genome sequence release. Designed for LightCycler® 480 I & II, LightCycler® PRO, and cobas® z 480 systems, it enables swift test deployment, strengthening outbreak response and surveillance in regions such as the Democratic Republic of Congo and Uganda.
What role does TIB MOLBIOL’s rapid response library play in Ebola Bundibugyo virus assay development?
TIB MOLBIOL maintains a rapid response library of 15,000 test pre-designs and over 3,000 positive control materials. Combined with oligonucleotide synthesis expertise, this allows rapid evaluation of multiple primer and probe combinations for the Ebola Bundibugyo virus within hours. This off-the-shelf model lets laboratories quickly access ready-to-use assay designs during the critical early phases of an outbreak.
Why are RUO molecular assays critical for managing Bundibugyo virus outbreaks before IVD approval?
RUO assays are shipped directly to laboratories for validation long before fully approved in-vitro diagnostics or emergency-use tests are available, a process that can take months or years. For Bundibugyo virus, which lacks approved vaccines or specific treatments and may evade some frontline tests, rapid, accurate molecular RUO testing is essential to avoid diagnostic delays, support surveillance, and guide early outbreak control decisions.